CHMA Chiasma, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

CHMA [NASD]

Chiasma, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.35	Insider Own	4.52%	Shs Outstand	57.80M	Perf Week	-3.24%
Market Cap	224.30M	Forward P/E	-	EPS next Y	-1.03	Insider Trans	0.38%	Shs Float	48.91M	Perf Month	-11.62%
Income	-56.20M	PEG	-	EPS next Q	-0.39	Inst Own	57.60%	Short Float	3.71%	Perf Quarter	-14.35%
Sales	-	P/S	-	EPS this Y	17.10%	Inst Trans	2.65%	Short Ratio	3.43	Perf Half Y	-20.16%
Book/sh	1.23	P/B	3.15	EPS next Y	38.00%	ROA	-58.20%	Target Price	-	Perf Year	-24.37%
Cash/sh	1.16	P/C	3.34	EPS next 5Y	46.30%	ROE	-73.50%	52W Range	2.88 - 7.75	Perf YTD	-21.77%
Dividend	-	P/FCF	-	EPS past 5Y	-51.60%	ROI	-	52W High	-49.94%	Beta	1.57
Dividend %	-	Quick Ratio	4.40	Sales past 5Y	-	Gross Margin	-	52W Low	34.72%	ATR	0.19
Employees	48	Current Ratio	4.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	29.64	Volatility	3.16% 4.31%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-101.50%	Profit Margin	-	Rel Volume	0.32	Prev Close	3.89
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 AMC	Payout	-	Avg Volume	529.75K	Price	3.88
Recom	1.80	SMA20	-5.03%	SMA50	-17.12%	SMA200	-19.90%	Volume	167,999	Change	-0.26%

Aug-13-20

Initiated

Jefferies

Buy

Jul-31-19

Initiated

Piper Jaffray

Overweight

$11

Feb-14-19

Initiated

H.C. Wainwright

Buy

$11

Jan-17-17

Downgrade

Barclays

Equal Weight → Underweight

$5.50 → $2.50

Apr-25-16

Downgrade

Barclays

Overweight → Equal Weight

$40 → $5.50

Aug-10-15

Initiated

Barclays

Overweight

$40

Oct-01-20 07:00AM	Chiasma Announces Planned Transition of Former CEO GlobeNewswire
Sep-24-20 10:46AM	3 Strong Buy Healthcare Stocks Under $5 With Triple-Digit Growth Prospects TipRanks
Sep-08-20 08:00AM	Chiasma to Participate in Two September Investor Conferences GlobeNewswire
Aug-31-20 08:00AM	Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly GlobeNewswire +9.15%
Aug-17-20 02:01PM	Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares? Simply Wall St.
08:00AM	Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism GlobeNewswire
Aug-11-20 02:30AM	Chiasma (CHMA) Q2 2020 Earnings Call Transcript Motley Fool -5.00%
Aug-10-20 04:05PM	Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness GlobeNewswire
Aug-03-20 04:01PM	Chiasma to Report Second Quarter 2020 Results on August 10 GlobeNewswire +6.29%
Jul-27-20 04:01PM	Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly GlobeNewswire
Jul-08-20 09:21PM	Were Hedge Funds Right About Chiasma Inc (CHMA)? Insider Monkey
Jul-01-20 11:53AM	Why Chiasmas Shares Are Down Today Motley Fool -13.57%
09:05AM	Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants GlobeNewswire
08:55AM	Is Chiasma (CHMA) Stock a Solid Choice Right Now? Zacks
Jun-30-20 04:30PM	Chiasma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
Jun-29-20 09:52AM	Are Options Traders Betting on a Big Move in Chiasma (CHMA) Stock? Zacks -7.57%
Jun-26-20 01:28PM	Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog GlobeNewswire -7.46%
08:28AM	The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts Benzinga
Jun-16-20 06:14AM	Companies Like Chiasma (NASDAQ:CHMA) Are In A Position To Invest In Growth Simply Wall St.
Jun-04-20 08:28PM	Edited Transcript of CHMA earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-08-20 04:30PM	Chiasma Inc (CHMA) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:05PM	Chiasma Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-30-20 04:01PM	Chiasma To Report First Quarter Financial Results On May 7, 2020 GlobeNewswire -5.14%
Apr-22-20 04:45PM	Chiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-08-20 07:00AM	Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners GlobeNewswire +13.03%
Mar-31-20 04:56PM	Edited Transcript of CHMA earnings conference call or presentation 16-Mar-20 9:00pm GMT Thomson Reuters StreetEvents
Mar-16-20 04:05PM	Chiasma Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire -10.58%
03:00PM	Chiasma, Inc. to Host Earnings Call ACCESSWIRE
Mar-09-20 04:05PM	Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020 GlobeNewswire
Feb-06-20 10:40AM	Wall Street Pros: These 3 Stocks Can Double Next Year TipRanks
Jan-26-20 09:17AM	Does Chiasma, Inc. (NASDAQ:CHMA) Have A High Beta? Simply Wall St.
Jan-13-20 07:00AM	Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission GlobeNewswire
Jan-10-20 07:00AM	Chiasma Provides Corporate Update and Previews 2020 Milestones GlobeNewswire
Dec-20-19 08:12AM	The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering Benzinga
Dec-19-19 04:05PM	Chiasma Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-14-19 08:59PM	Hedge Funds Have Never Been This Bullish On Chiasma Inc (CHMA) Insider Monkey
Nov-26-19 04:05PM	Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-22-19 02:27AM	Edited Transcript of CHMA earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 04:05PM	Chiasma to Present at the 13th Acromegaly Consensus Conference GlobeNewswire
Nov-11-19 09:39AM	Hedge Funds Have Never Been More Bullish On Chiasma Inc (CHMA) Insider Monkey
Nov-05-19 04:05PM	Chiasma Reports Third Quarter 2019 Results GlobeNewswire
Nov-01-19 08:00AM	Chiasma Supports Acromegaly Awareness Day GlobeNewswire
Oct-29-19 08:00AM	Chiasma to Report Third Quarter Financial Results on November 5, 2019 GlobeNewswire
Oct-28-19 07:26AM	We're Not Very Worried About Chiasma's (NASDAQ:CHMA) Cash Burn Rate Simply Wall St.
Sep-25-19 08:00AM	Chiasma to Present at the Cantor 2019 Global Healthcare Conference GlobeNewswire
Sep-18-19 06:30AM	3 Small Biotechs With Favorable Risk Vs. Reward Profiles TheStreet.com
Sep-17-19 09:00AM	What Makes Chiasma (CHMA) a New Buy Stock Zacks
Sep-13-19 08:19AM	What Kind Of Shareholder Owns Most Chiasma, Inc. (NASDAQ:CHMA) Stock? Simply Wall St.
Sep-05-19 04:05PM	Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly GlobeNewswire
Aug-31-19 10:23PM	Edited Transcript of CHMA earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-16-19 09:00AM	Chiasma (CHMA) Upgraded to Buy: Here's Why Zacks
Aug-09-19 01:23PM	Chiasma Inc (CHMA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 04:05PM	Chiasma Reports Second Quarter 2019 Results GlobeNewswire
Aug-01-19 04:05PM	Chiasma to Report Second Quarter Financial Results on August 8, 2019 GlobeNewswire -6.38%
Jul-31-19 01:48PM	Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-26-19 09:06AM	Chiasma Announces Pricing of Underwritten Public Offering of $55.0 Million of Common Stock GlobeNewswire
Jul-25-19 04:01PM	Chiasma Announces Proposed Offering of Common Stock GlobeNewswire -12.92%
Jul-23-19 09:39AM	Here Is What's Driving The Rally In Chiasma Benzinga +26.77%
06:00AM	Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly GlobeNewswire
Jul-15-19 12:55PM	One Thing To Remember About The Chiasma, Inc. (NASDAQ:CHMA) Share Price Simply Wall St.
Jun-28-19 02:19PM	18 Stocks Joining The Russell Indices Benzinga
07:32AM	The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO Benzinga
Jun-27-19 04:10PM	Chiasma Set to Join Russell 3000® Index GlobeNewswire
04:05PM	Chiasma Provides Update on Ongoing Mycapssa® Phase 3 Clinical Trials GlobeNewswire
Jun-06-19 07:37AM	The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering Benzinga
Jun-05-19 04:05PM	Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa® GlobeNewswire
May-30-19 08:50AM	Chiasma (CHMA) Catches Eye: Stock Jumps 9.7% Zacks
05:59AM	Will Chiasma to Surge Higher? Zacks
May-24-19 06:52AM	Edited Transcript of CHMA earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-14-19 04:05PM	Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Development and Definitive Commercial Supply Agreement GlobeNewswire
May-09-19 06:45PM	Chiasma: 1Q Earnings Snapshot Associated Press
04:05PM	Chiasma Reports First Quarter 2019 Results GlobeNewswire
Apr-30-19 04:05PM	Chiasma to Report First Quarter Financial Results on May 9, 2019 GlobeNewswire
Apr-25-19 02:14PM	Shareholders Are Raving About How The Chiasma (NASDAQ:CHMA) Share Price Increased 312% Simply Wall St.
Apr-03-19 09:25AM	Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters Option GlobeNewswire
Mar-29-19 09:25AM	Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock GlobeNewswire -9.72%
Mar-28-19 05:19PM	5 Stocks Moving In Thursday's After-Hours Session Benzinga
04:01PM	Chiasma Announces Proposed Offering of Common Stock GlobeNewswire
Mar-21-19 04:05PM	Chiasma Announces Three Poster Presentations at ENDO 2019 GlobeNewswire -18.87%
Mar-08-19 04:05PM	Chiasma Reports Fourth Quarter and Year End 2018 Results GlobeNewswire
Mar-04-19 04:05PM	Chiasma to Participate in Three Investor Conferences in March GlobeNewswire +8.70%
Feb-28-19 08:00AM	Chiasma Announces Support for Rare Disease Day 2019 GlobeNewswire
Feb-27-19 12:56PM	Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares? Simply Wall St.
Jan-03-19 04:05PM	Chiasma Previews Important Upcoming Milestones GlobeNewswire +14.77%
Dec-21-18 09:47AM	Do Directors Own Chiasma, Inc. (NASDAQ:CHMA) Shares? Simply Wall St.
Nov-21-18 08:55AM	Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-08-18 06:03PM	Chiasma: 3Q Earnings Snapshot Associated Press
04:05PM	Chiasma Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 08:00AM	Chiasma Supports Acromegaly Awareness Day GlobeNewswire
Oct-17-18 04:05PM	Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association GlobeNewswire
Oct-02-18 09:10AM	The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares Benzinga
Oct-01-18 04:01PM	Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly GlobeNewswire
Sep-20-18 01:57PM	One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA) Simply Wall St.
Sep-13-18 04:01PM	Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies GlobeNewswire
Aug-09-18 05:47PM	Chiasma: 2Q Earnings Snapshot Associated Press
04:05PM	Chiasma Reports Second Quarter 2018 Results GlobeNewswire
Jul-25-18 04:05PM	Chiasma Completes Enrollment of MPOWERED(TM) Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly GlobeNewswire
Jun-18-18 04:05PM	Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference GlobeNewswire
Jun-14-18 04:05PM	Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly GlobeNewswire
May-14-18 04:05PM	Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial GlobeNewswire -6.45%

Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KANNAN RAJ	Chief Executive Officer	Jul 14	Buy	4.20	10,000	42,000	17,095	Jul 15 06:57 PM
Mamluk Roni	Director	Feb 20	Option Exercise	0.09	82,186	7,397	82,186	Feb 21 04:43 PM
Mamluk Roni	Director	Feb 20	Sale	4.54	82,186	373,124	0	Feb 21 04:43 PM
Mamluk Roni	Director	Dec 20	Option Exercise	0.09	61,139	5,503	61,139	Dec 23 04:10 PM
Mamluk Roni	Director	Dec 20	Sale	5.51	61,139	336,876	0	Dec 23 04:10 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience